

COULD THIS BREAST CANCER TRIAL BE RIGHT FOR YOU?

The Elegant Study is a clinical trial testing a potential new treatment called elacestrant against standard endocrine or hormone-blocking therapy. It is for people with early-stage breast cancer that is hormone receptor positive (ER+) and HER2-negative, and has spread to the lymph nodes.

SCAN ME



clinicaltrials.gov



elegantstudy.com



A clinical trial may be one of your treatment choices if you have node-positive, ER-positive/HER2-negative early stage breast cancer.

Talk with your doctor and health care team about the risks and benefits of participating in an [elacestrant](#) clinical trial.




To take a closer look at the trial, please visit [elegantstudy.com](#)

For more information about the ELEGANT clinical trial, including full eligibility criteria and study centers, please visit [www.ClinicalTrials.gov](#) trial number **NCT06492616.**

WHAT IS ELACESTRANT?

Natural hormones like estrogen can help your tumor grow and spread to other parts of your body.¹

Elacestrant is a class of drug called selective estrogen receptor degrader (SERD). Elacestrant reduces estrogen activity and helps to prevent cancer cells from using estrogen to grow and spread.²



This trial is studying how safe and effective elacestrant is compared to endocrine therapy.

WHAT YOU NEED TO KNOW TO PARTICIPATE*

If interested, you will be asked to have some tests done to find out if you meet certain requirements to join the trial. Some tests may already be part of your current treatment plan. Some of those requirements include:

- 1 You are a woman or man aged **18 years** or older
- 2 You have been diagnosed with **ER-positive/HER2-negative early-stage, node-positive breast cancer**
- 3 You have **received between 2–5 years of endocrine therapy** for breast cancer
- 4 You had **surgery to remove the tumor 2–6 years ago**

***This is not a complete list of eligibility criteria for the clinical trial. Other inclusion or exclusion criteria may apply.**

WHAT WILL PARTICIPATING IN THIS CLINICAL TRIAL LOOK LIKE?



You will take one elacestrant tablet by mouth once a day or continue your endocrine therapy



You will be asked to have physical exams, bone density scans and blood tests periodically



You will be carefully monitored by your doctor and health care team



You will be asked to complete questionnaires about your normal day-to-day activities

Cost of elacestrant will be covered and provided to patients free of charge.

ER=estrogen receptor; HER2=human epidermal growth factor receptor 2.

1. Estrogen-dependent cancers: Causes, diagnosis & treatment. Cleveland Clinic. <https://my.clevelandclinic.org/health/diseases/10312-estrogen-dependent-cancers>. Accessed December 10, 2024. 2. Bidard FC, et al. *J Clin Oncol*. 2022;40(28):3246-3256. 3. Feng Y, et al. *Genes Dis*. 2018;5(2):77-106.

The safety and efficacy in this patient population is investigational and has not been established; marketing approval has not been granted by regulatory authorities for this early breast cancer indication, elacestrant is approved in the advanced breast cancer by the FDA and EMEA regulatory authorities.

THIS MATERIAL HAS BEEN DEVELOPED AND FUNDED BY MENARINI STEMLINE AND IS INTENDED FOR PARTICIPATING STUDY CENTERS AND REFERRAL SITES.